University of Kansas Medical Center, Kansas City, KS, USA.
Temple University, Philadelphia, PA, USA.
J Prim Care Community Health. 2022 Jan-Dec;13:21501319221110411. doi: 10.1177/21501319221110411.
Our study provides data on the prevalence of human papillomavirus (HPV) related disease and vaccination rates among users of pre-exposure prophylaxis (PrEP) in a primary care clinic. Results highlight an opportunity to partner HIV and HPV prevention efforts.
This is a retrospective chart review of PrEP patients in an urban Midwestern Family Medicine clinic. We conducted univariate analyses for HPV vaccination status and the prevalence of any HPV-related disease. We then examined bivariate relationships between vaccination status and insurance coverage, provider type, and age.
Of all 78 PrEP patients identified, 21.8% (n = 17) were vaccinated. Of the 59 patients 45 years or younger, 28.8% (n = 17) were vaccinated. There was no association between insurance or provider type and vaccination status. Patients 26 years or younger were 3 times more likely to be vaccinated than those ages 27 to 45 (56.3% vs 18.6%, = .0011). Three unvaccinated patients had HPV-related disease.
Despite ongoing risk of HPV infection and frequent interaction with the medical system, this study found most PrEP users continue to be unvaccinated. This is a significant missed opportunity for HPV prevention. With the FDA approval of the HPV vaccine for individuals age 9 to 45, PrEP patients in this age range would benefit from clinicians partnering HPV vaccination with PrEP prescribing.
我们的研究提供了在一家初级保健诊所中使用暴露前预防（PrEP）的患者中人类乳头瘤病毒（HPV）相关疾病和疫苗接种率的数据。研究结果突显了合作开展 HIV 和 HPV 预防工作的机会。
这是对一家中西部城市家庭医学诊所中 PrEP 患者的回顾性图表审查。我们对 HPV 疫苗接种状况和任何 HPV 相关疾病的患病率进行了单变量分析。然后，我们检查了疫苗接种状况与保险覆盖范围、提供者类型和年龄之间的双变量关系。
在所确定的 78 名 PrEP 患者中，21.8%（n=17）接种了疫苗。在 45 岁或以下的 59 名患者中，28.8%（n=17）接种了疫苗。保险或提供者类型与疫苗接种状况之间没有关联。26 岁或以下的患者接种疫苗的可能性是 27 至 45 岁患者的 3 倍（56.3%比 18.6%，=0.0011）。有 3 名未接种疫苗的患者患有 HPV 相关疾病。
尽管存在持续的 HPV 感染风险并且经常与医疗系统互动，但本研究发现大多数 PrEP 用户仍然未接种疫苗。这是 HPV 预防的一个重大错失机会。随着 FDA 批准 HPV 疫苗用于 9 至 45 岁的人群，该年龄段的 PrEP 患者将受益于临床医生将 HPV 疫苗接种与 PrEP 处方相结合。
